Nephrology ·
FDA clears Fresenius CKRT system for citrate anticoagulation; AI alerts fail to cut kidney events; SGLT2 inhibitor use rises after Klinrisk flags
Listen to this post
read by AI voices · all episodesTHE SHORT READ
The Food and Drug Administration (FDA) cleared Fresenius Medical Care's multiFiltratePRO continuous kidney replacement therapy system on Oct. 19. At American Society of Nephrology (ASN) Kidney Week 2026, AI-triggered pharmacist alerts did not reduce kidney events in a cluster-randomized trial, and posters reported results for Klinrisk risk flagging and the Kidney Care Choices Model.
THE DETAILS
- FDA Oct 19, 2026The Food and Drug Administration (FDA) cleared Fresenius Medical Care's multiFiltratePRO continuous kidney replacement therapy (CKRT) system on Oct. 19 and approved Cienby sodium citrate and Calrezdy calcium chloride solutions, the company said Oct. 21. Fresenius said it is the first CKRT system and dedicated solutions package in the U.S. for on-label regional citrate anticoagulation, using its Ci-Ca Protocol during continuous venovenous hemodialysis or hemodiafiltration in patients weighing 40 kg or more with acute renal failure. Its integrated technology eliminates the need for separate citrate and calcium pumps, the company said. The launch begins as a controlled rollout.Source: Fresenius Medical Care
- AI Oct 22, 2026In the MEnD-AKI cluster-randomized trial presented at Kidney Week 2026, investigators randomized 38 hospital service clusters across eight hospitals to a pharmacist intervention or usual care. A deep learning model predicted each patient's risk of progressing to stage 2 or higher acute kidney injury within 48 hours, and tiered alerts led pharmacists to send recommendations to physicians via telemedicine. The primary end point, MAKE30, occurred in 50.8% of intervention and 42.9% of usual care patients (adjusted odds ratio 1.05; 95% CI 0.82 to 1.35), not a significant difference, HCPLive reported Oct. 22. Investigators said more actionable, real-time alerts are needed.Source: HCPLive
- Technology Oct 23, 2026In a quality improvement initiative in a large U.S. nephrology practice, presented as a Kidney Week 2026 poster, patients with a 5-year risk of progressive chronic kidney disease of at least 25% on Klinrisk, a model that predicts progression from routine laboratory data, were flagged as high risk. The analysis compared 51,097 patients at baseline with 54,257 at follow-up. Among high-risk patients, SGLT2 inhibitor use rose from 30.7% to 37.9%, and urine albumin-to-creatinine ratio testing across all patients rose from 43.0% to 50.7%, AJMC reported Oct. 23. The study was funded by Klinrisk and AstraZeneca.Source: AJMC
- Payment Oct 23, 2026A retrospective Kidney Week 2026 poster compared Medicare beneficiaries in Comprehensive Kidney Care Contracting (CKCC) practices, part of the Kidney Care Choices Model of the Centers for Medicare & Medicaid Services (CMS), with matched beneficiaries outside the model in 2022 and 2023. Relative to comparison practices, CKCC practices improved permanent vascular access at hemodialysis initiation by 1.44 percentage points per quarter, and aligned beneficiaries with stage 4 to 5 chronic kidney disease had $3,876 lower annual Medicare costs, AJMC reported. CMS's evaluation of the full model found no significant effect on total Medicare Parts A and B payments in 2023.Source: AJMC
The weekly innovation roundup for nephrology, published every Sunday for the week before; every item links to its sources. Latest nephrology news · All specialties